Despite the lack of difference in recombinant enzyme turnover, GWAS of MTARC1 p.A165T shows remarkably broad protection from liver fibrosis, steatosis, and cirrhosis and a benefit in NASH. This evidence concerns the gene MTARC1 and metabolic dysfunction-associated steatohepatitis.